ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · IEX Real-Time Price · USD
5.23
+0.20 (3.98%)
At close: Nov 29, 2022 4:00 PM
5.20
-0.03 (-0.57%)
After-hours: Nov 29, 2022 4:08 PM EST
3.98%
Market Cap 2.01B
Revenue (ttm) 557,000
Net Income (ttm) -399.61M
Shares Out 400.06M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,039,675
Open 5.04
Previous Close 5.03
Day's Range 4.99 - 5.26
52-Week Range 2.6 - 8.01
Beta n/a
Analysts Buy
Price Target 9.18 (+75.5%)
Earnings Date Aug 18, 2022

About IBRX

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, incl... [Read more]

Industry Biotechnology
Founded 2014
CEO Patrick Soon-Shiong
Employees 760
Stock Exchange NASDAQ
Ticker Symbol IBRX
Full Company Profile

Financial Performance

In 2021, ImmunityBio's revenue was $934,000, an increase of 54.38% compared to the previous year's $605,000. Losses were -$346.79 million, 56.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 75.53% from the latest price.

Price Target
$9.18
(75.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference

CULVER CITY, Calif.--( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler ...

1 week ago - Business Wire

LadRx Corporation Issues Corporate Update for 3Q22

LOS ANGELES--( BUSINESS WIRE )--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today is...

1 week ago - Business Wire

ImmunityBio to Participate in the Jefferies London Healthcare Conference

CULVER CITY, Calif.

1 month ago - Business Wire

7 Unknown Biotech Stocks That Could Rocket in 2023

Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

2 months ago - InvestorPlace

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasi...

CULVER CITY, Calif.--(BUSINESS WIRE)--The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein as a treatment for...

4 months ago - Business Wire

7 Best Pharmaceutical Stocks to Buy Now

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

Other symbols: AMGNBMYGILDLLYPFEVTRS
4 months ago - InvestorPlace

ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Canc...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading clinical-stage immunotherapy company, today announced new positive data from the company's pivotal Phase 2/3 trial for B...

5 months ago - Business Wire

ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle In...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has submitted a Biologics License Application (BLA) to the U.S. Food an...

6 months ago - Business Wire

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) An...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Cl...

7 months ago - Business Wire

ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T C...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the first participants have been enrolled in a study that is part of ...

7 months ago - Business Wire

ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-...

7 months ago - Business Wire

Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio's...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced study results that further demonstrate the potential for use of memory-lik...

8 months ago - Business Wire

ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting

ImmunityBio Inc (NASDAQ: IBRX) announced data from its bladder cancer trial (QUILT-3.032) Phase 2/3 study of intravesical BCG plus Anktiva (N-803). The data showed sustained complete response rates in p...

9 months ago - Benzinga

ImmunityBio Completes Acquisition of Athenex's Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced the successful completion of its acquisition of the leaseh...

Other symbols: ATNX
9 months ago - Business Wire

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Set...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive data from the company's late-stage bladder cancer trial (QUILT-3....

9 months ago - Business Wire

ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill' HIV Cure Strategy to Reduce HIV Viral Load...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced promising study results that demonstrate the activation of CD4+ and CD8+ T...

9 months ago - Business Wire

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial

ImmunityBio Inc (NASDAQ: IBRX) has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall survival rate doubled compared to the historical ...

10 months ago - Benzinga

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival o...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88...

10 months ago - Business Wire

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced that it has entered into a definitive agreement to acquire...

10 months ago - Business Wire

ImmunityBio Awarded Seminal Patent on Natural Killer Cells

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has been granted a U.S. patent (11,207,350 B2) for a novel natural killer (NK) cell therap...

10 months ago - Business Wire

Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture

Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine. Upon...

Other symbols: AMRS
10 months ago - Benzinga

AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE

EMERYVILLE, Calif. and CULVER CITY, Calif.

Other symbols: AMRS
10 months ago - PRNewsWire

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative dis...

11 months ago - Business Wire

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Pha...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing in 2021, wi...

11 months ago - Business Wire

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the expansion of the company's cancer and infectious disease vaccine progr...

1 year ago - Business Wire